Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAF(V600)-mutant melanoma. We performed a nonrandomized, open-label phase II study,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: van Herpen, Carla M.L., Agarwala, Sanjiv S., Hauschild, Axel, Berking, Carola, Beck, J. Thaddeus, Schadendorf, Dirk, Jansen, Rob, Queirolo, Paola, Ascierto, Paolo A., Blank, Christian U., Heinrich, Michael C., Pal, Rupam R., Derti, Adnan, Antona, Victor, Nauwelaerts, Heidi, Zubel, Angela, Dummer, Reinhard
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2019
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442999/
https://ncbi.nlm.nih.gov/pubmed/30956763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26753
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia